md-medicaldata

Authors

 

Goran Đenadić

Služba za patološko-anatomsku dijagnostiku, Opšta bolnica “Dr Laza K. Lazarević”, Šabac, Srbija

 

UDK: 616.155.392-037

The paper was received / Rad primljen: 01.12.2022.

Accepted / Rad prihvaćen: 21.12.2022.

 

Correspondence to:

Dr sci. med. Goran Đenadić,
patolog i citolog
Služba za patologiju
Opšta bolnica Šabac
Popa Karana 4
15000 Šabac
e-mail: gorandjenadic@gmail.com

 

 

Sažetak

 

 

Triholeukemija kao specifičan klinički entitet objavljena je pre 50 godina. Klinički ishod sa srednjim preživljavanjem nakon dijagnoze bio je 4 godine. Uvođenjem savremene terapije primećena su značajna poboljšanja u lečenju pacijenata. Ali triholeukemija ostaje hronična bolest opasna po život po svojoj prirodi i po razvoju brojnih komplikacija, posebno infekcija, posebno usled pandemijske korone, sa izvesnim smrtnim ishodom. Diskutovano je o forenzičkom aspektu triholeukemije i njenom uticaju na sposobnost pacijenta u adekvatnom učestvovanju u sudskom postupku. Autor iznosi argumente da pacijenti sa aktivnom triholeukemijom nemaju mogućnost da kompetentno učestvuju u sudskim postupcima u cilju iznošenja argumenata u prilog sopstvene odbrane.

 

Ključne reči:

triholeukemija, forenzički aspekt, sudski postupak.

 

 

 

Abstract

Hairy cell leukemia as a specific clinical entity was published 50 years ago. The clinical outcome with median survival after diagnosis was 4 years. With the introduction of modern therapy, marked improvements in patient responses were observed. But tricholeukemia remains a life-threatening disease by its very nature and the development of numerous complications, especially infections and especially due to the pandemic corona. Forensic aspect of hairy cell leukemia and their impact on ability to conduct court proceedings, were discussed. The author presents arguments that patients with active tricholeukemia do not have the ability to competently participate in court proceedings.

 

Key words:

Hairy cell leukemia, forensic aspect, court proceedings.

 

 

 

 

References:

1. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1):21-8.
2. Volkert Goulart A, Lessmann Reckziegel JC, Córdova Pinto CA. Tricholeukemia and therapeutic perspectives in a refractory case. International Journal of Development Research, 2019; 09(03), 26181-26184.
3. Colovic N, Marisavljevic D, Kraguljac-Kurtovic N, Bogdanovic A, Gotic M. CD56-Positive acute myeloid leukemia following treatment of hairy cell leukemia with cladribine – Report of 2 cases and review of the literature. Arch Iran Med. May 2019;22(5):269-271.
4. Grever M, Andritsos L, Banerji V, Barrientos JC, Bhat S, Blachly JS, et al. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines Leukemia. 2021;35(7):1864-1872.
   

PDF: 05-Đenadić MD-Medical Data 2022;14(3) 77-80.pdf